The Ministry of health has recorded a sharp drop in the price of HIV drugs


Centralization and import substitution

The HIV drugs fell sharply in 2016, said health Minister Veronika Skvortsova at the II all-Russian forum of specialists in the prevention and treatment of HIV/AIDS. According to her, the price of some medicines fell 17.5%. As a result, the cost of first-line therapy (set of drugs prescribed for the detection of disease), decreased in two times, the Minister said.

Managed to save due to a partial centralization of procurement of drugs and import substitution, said Skvortsova. Names depreciating medicines it may lead.

In a press-service of the Ministry of health announced that it is on eight medications. Stronger just dropped the price of the drug tenofovir, from 70 thousand to 3.7 thousand RUB over the annual course of treatment or 95%, considered in ITPCru. As a result, the number of patients receiving this medication, increased 10-fold, from 3.7 thousand to 37.5 thousand. This was achieved due to growth in competition in the last year and a half on the market there are three national analogue of tenofovir, which produce pharmaceutical company BIOCAD, JSC “pharmasyntez” and OOO “Technology of drugs”, said the head of monitoring ITPCru Alexei Mikhailov.

The remaining products, which says the Ministry of health, fell 2% to 52% (according ITPCru).

In addition to import substitution, the results gave a partial centralization of public procurement of medicines Agency. Now the Ministry of health independently acquires drugs for the Federal penitentiary service and Federal health agencies, in 2017, all procurement of medications for HIV will become a Federal. “The average annual cost of first line therapy one patient in the procurement of the Ministry of health amounted to 31.8 thousand rubles., and with regional procurement — 50,3 thousand RUB”. — said the Agency.

Expensive patents

Much cheaper drugs out of patent protection: they are no longer subject to the exclusive rights of the same pharmaceutical companies, so other companies can produce cheaper counterparts is the generics. The cost of vital patented drugs for a year practically has not changed. First of all, it concerns three drugs, the total value of procurement which is 30 November 2016, according ITPCru, amounted to 9.1 billion rubles — this is almost half of the budget for the purchase of all drugs for HIV treatment. Only for the purchase of such medicines in 2016, has spent about 20 billion rubles.

To reduce the price of these drugs need to negotiate prices with patentees. If agreement fails, we should limit their rights, allowing to produce analogues of the Russian manufacturers, I’m sure Mikhailov from ITPCru. The initiative, which would limit the rights of the patent holder, was recently sponsored by the Federal Antimonopoly service.

Another drug, tenofovir+emtricitabine, was recommended by who to treat HIV, but were not included in the list of vital because of its high price — 150 thousand RUB over the annual course. Only the inclusion of a drug in the list warrants its purchase by the state, otherwise the patients have to purchase it yourself. On 15 November the Ministry of health refused to expand the list for lack of budget.

Source